This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human IL-7 R alpha / CD127 Protein, Mouse IgG2a Fc Tag
catalog :
IL7-H5258
quantity :
1 mg, 100 ug
price :
2100 USD, 320 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
IL7-H5258
product name :
Human IL-7 R alpha / CD127 Protein, Mouse IgG2a Fc Tag
quantity :
1 mg, 100 ug
price :
2100 USD, 320 USD
quantity & price :
$320/100ug,$2100/1mg (500ug × 2)
target :
IL-7 R alpha
host species :
Human
By Tag :
Mouse IgG Fc Tag
Research :
For Research Use Only
Source :
Human IL-7 R alpha, Mouse IgG2a Fc Tag (IL7-H5258) is expressed from human 293 cells (HEK293). It contains AA Glu 21 - Gly 236 (Accession # P16871-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human IL-7 R alpha, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Interleukin-7 receptor subunit alpha (IL7Ra) is also known as CD antigen CD127, which belongs to the type I cytokine receptor family and type 4 subfamily. IL7Ra /CD127 contains 1 fibronectin type-III domain. IL7Ra /CD127 is expressed on various cell types, including naive and memory T cells and many others. IL7Ra /CD127 is receptor for interleukin-7 and also acts as a receptor for thymic stromal lymphopoietin (TSLP). The IL7 receptor is a heterodimer of IL7R and IL2RG. The TSLP receptor is a heterodimer of CRLF2 and IL7R.
References :
(1) Noguchi M., et al., 1994, Science 262 (5141): 1877–80.
(2) Kroemer RT., et al., 1997, Protein Eng. 9 (12): 1135–42.
(3) McElroy C.A., et al., 2009, Structure 17:54-65.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments